Ovid Therapeutics Inc. OVID
2.58 USD -0.20 (-7.37%)
Nov 12, 2026, 11:21 AM EST
2.57 Day range 2.77
1.18 52-week range 3.11
- YTD
- +57.98%
- 1 year
- +95.08%
News
benzinga.com Ovid Therapeutics Q3 EPS $(0.10) Misses $(0.09) Estimate Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 41.18 percent increase over losses of…
globenewswire.com Ovid Therapeutics Reports Business Updates and Third Quarter 2026 Financial Results OV329 is advancing in a global, Phase 2 focal epilepsy study expected to read out in H2 2027 Ovid is enrolling patients in ongoing photosensitivity study intended to demonstrate the anticonvulsant…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock moved upwards by 10.0% to $0.04 during Monday's after-market session. The company's market cap stands at $1.2 million. Fractyl Health (NASDAQ:GUTS)…
defenseworld.net Critical Comparison: Ovid Therapeutics (NASDAQ:OVID) & Ono Pharmaceutical (OTCMKTS:OPHLF) Ono Pharmaceutical (OTCMKTS:OPHLF - Get Free Report) and Ovid Therapeutics (NASDAQ: OVID - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the…
globenewswire.com Ovid Therapeutics to Participate in Upcoming Investor Conferences NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant…
benzinga.com Wolfe Research Initiates Coverage On Ovid Therapeutics with Outperform Rating, Announces Price Target of $5 Wolfe Research initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Outperform rating and announces Price Target of $5.
benzinga.com Cantor Fitzgerald Initiates Coverage On Ovid Therapeutics with Overweight Rating Cantor Fitzgerald analyst Imogen Mansfield initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Overweight rating.
benzinga.com Guggenheim Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $7 Guggenheim analyst Delma Caiati initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Buy rating and announces Price Target of $7.
benzinga.com Guggenheim Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $7 Guggenheim analyst Delma Caiati initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Buy rating and announces Price Target of $7.
benzinga.com Vail Resorts, Inventiva And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. futures mixed as Vail Resorts fell after a Q4 loss miss despite beating sales estimates; several stocks also declined premarket.- benzinga.com HC Wainwright & Co. Maintains Buy on Ovid Therapeutics, Raises Price Target to $5 HC Wainwright & Co. analyst Raghuram Selvaraju maintains Ovid Therapeutics (NASDAQ:OVID) with a Buy and raises the price target from $4 to $5.
benzinga.com Ovid Therapeutics Q2 EPS $(0.08) Beats $(0.12) Estimate, Sales $733.000K Beat $30.000K Estimate Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.12) by 27.27 percent. This is a 33.33 percent decrease over losses of…
benzinga.com Oppenheimer Maintains Outperform on Ovid Therapeutics, Raises Price Target to $9 Oppenheimer analyst Kostas Biliouris maintains Ovid Therapeutics (NASDAQ:OVID) with a Outperform and raises the price target from $7 to $9.- benzinga.com Ovid Therapeutics Promotes Charles Carter As CFO Succeeding Jeffrey Rona Kevin Norrett, a proven leader in advancing corporate strategy through value-creating transactions, will be appointed as Chief Business OfficerCharles Carter promoted to Chief Financial Officer,…
benzinga.com Rivian, Micron And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. stock futures mixed, Nasdaq 100 falls 200 pts. Rivian (RIVN) drops after public offering announcement. Other stocks also down in pre-market.
benzinga.com uniQure's Experimental Drug Shows Early Promise In Difficult-To-Treat Epilepsy uniQure reported early seizure reductions in an AMT-260 epilepsy study, with no treatment-related serious adverse events.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
benzinga.com Earnings Scheduled For March 18, 2026 - benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday 
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session 
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this…
- benzinga.com Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating…
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday's session saw 184 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's trading, 517 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 838 companies hit new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 149 companies reached new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 198 companies reached new 52-week lows.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2021
- benzinga.com 65 Biggest Movers From Friday Gainers Urovant Sciences Ltd. (NASDAQ: UROV) shares jumped 93.5% to close at $16.02 on Friday after the company late Thursday announced Sumitovant Biopharma will acquire the remaining stake in the…
- benzinga.com 54 Stocks Moving In Friday's Mid-Day Session Gainers Urovant Sciences Ltd. (NASDAQ: UROV) shares climbed 94% to $16.06 after the company late Thursday announced Sumitovant Biopharma will acquire the remaining stake in the company for $16.25 per…
- benzinga.com Stocks That Hit 52-Week Highs On Friday Friday's morning session saw 144 companies set new 52-week highs.
- benzinga.com 62 Biggest Movers From Yesterday Gainers
- benzinga.com 86 Biggest Movers From Yesterday Gainers SCWorx Corp. (NASDAQ: WORX) shares climbed 424.9% to close at $12.02 on Monday after the company reported a first installment of purchase order for 48 million coronavirus rapid testing units.
- benzinga.com 34 Stocks Moving in Tuesday's Pre-Market Session
- benzinga.com The Daily Biotech Pulse: Flexion Receives FDA Nod For Zilretta Label Expansion, Astellas Goes Shopping
- benzinga.com The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares
- benzinga.com Stocks That Hit 52-Week Highs On Monday
- benzinga.com 52 Biggest Movers From Wednesday
- benzinga.com 64 Biggest Movers From Yesterday
- benzinga.com Stocks Which Set New 52-Week Low Today, Wed., Jan. 2, 2019